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Desmoid tumours are benign, myofibroblastic stromal neoplasms common in Gardner’s syndrome, which is a
subtype of familial adenomatous polyposis characterized by colonic polyps, osteomas, thyroid cancer, epidermoid
cysts, fibromas and sebaceous cysts. The primary treatment is surgery, followed by adjuvant radiotherapy, but the
local recurrence rate is high, and wide resection can result in debilitating loss of function. We report the case
of a 39-year-old man with Gardner’s syndrome who had already undergone a total prophylactic colectomy. He
developed desmoid tumours localized in the mesenteric root, abdominal wall and dorsal region, which were
treated from 2003 through 2013 with several surgical procedures and percutaneous radiofrequency ablation. In
2008 and 2013, RFA was applied under ultrasonographic guidance to two desmoid tumours localized in the dorsal
thoracic wall. The outcomes were low-grade pain and one case of superficial skin necrosis, but so far there has been
no recurrence of desmoid tumours in these locations. Surgical resection remains the first-line therapy for patients
with desmoid tumours, but wide resection may lead to a poor quality of life. Radiofrequency ablation is less invasive
and expensive and is a possible therapeutic option for desmoid tumours in patients with Gardner’s syndrome.
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Desmoid tumours (DTs) are uncommon, histologically
benign, myofibroblastic neoplasms that arise from mus-
culoaponeurotic stromal elements. DTs occur rarely in
the general population, accounting for approximately
0.03% of all neoplasms and less than 3% of all soft-tissue
tumours. The estimated incidence of the spontaneous
form is 2million to 4 per million per year [1-3], but DTs
are relatively common in patients with familial aden-
omatous polyposis (FAP), with an incidence of 3.5% to
32% and a higher incidence of 29% in the original kindred
with Gardner’s syndrome [4]. Gardner’s syndrome (GS) is
a FAP subtype characterized by a high occurrence of DTs,
colonic polyps and extraabdominal tumours, including
osteomas of the skull, thyroid cancer, epidermoid cysts,
fibromas and sebaceous cysts [5]. DTs can develop* Correspondence: l.cobianchi@smatteo.pv.it
1General Surgery 1, Fondazione IRCCS Policlinico San Matteo, Viale Camillo
Golgi 19, 27100 Pavia, Italy
Full list of author information is available at the end of the article
© 2014 Cobianchi et al.; licensee BioMed Cent
Commons Attribution License (http://creativec
reproduction in any medium, provided the or
Dedication waiver (http://creativecommons.or
unless otherwise stated.anywhere in the body and generally occur in intra-
and extraabdominal anatomical locations. The most com-
mon locations are the extremities (around the limb girdles
and proximal extremities), the abdominal wall and in-
traabdominal and mesenteric sites. Depending on the
location, DTs tend to infiltrate adjacent organs, extend
along fascial planes and compress blood vessels and
nerves, creating severe symptoms such as intestinal
obstruction and bowel ischemia [6-8]. The biological
behaviour of DTs, such as growth and recurrence
rates and age and sex predilection, are considered unpre-
dictable and vary primarily by location. Local recurrence
rates for intraabdominal tumours are higher than those of
extraabdominal tumours, reported to be 57% to 86%
[9,10]. Despite such extant data, the natural history of DTs
remains poorly understood [11]. The first-line therapy for
patients with locally circumscribed DTs remains surgical
resection. The standard surgical goal is complete resection
with negative microscopic margins; however, wide re-
section can result in debilitating loss of function. Theral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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intraoperatively from scars and connective tissue, so R0
resection is not always possible, and, consequently, adju-
vant radiotherapy is often applied. DTs, however, have a
high local recurrence rate after surgery and/or radiother-
apy. In this report, we introduce radiofrequency ablation
(RFA) as a treatment option for DTs in a patient with GS.
Case presentation
A 39-year-old man with GS was referred to our institution
in April 2002. He was known to have a positive family
history of GS. In 1996, he underwent a total prophylactic
colectomy and subsequently developed DTs localized in
the mesenteric root, abdominal wall and dorsal region.
These DTs were judged to be untreatable by another med-
ical centre and were treated with sulindac in our oncologic
department without any benefit. In 2002, the patient was
referred to our centre because of the presence of multiple
giant DTs in the abdominal wall, which had caused ab-
dominal visceral compression and intestinal obstruction.
The patient underwent a successful radical surgical resec-
tion of the abdominal DTs. Since 2005, the patient had
experienced recurrence of DTs in the previous location
and in the right lateral thoracic wall and right infrascapu-
lar and left subscapular regions. We decided on two treat-
ment approaches for these masses: surgical removal of the
entire tumours and percutaneous RFA. Between 2003 and
2013, several surgical interventions for desmoid mass
excision were carried out. In 2008 and 2013, RFA was
planned and applied to two DTs localized in the dorsal
thoracic wall. The systems used in the RFA procedures
have been described in detail elsewhere [12,13]. In brief,
they utilize a commercially available RF generator (Model
TAG 100, Invatec Srl, Roncadelle, Italy, or Model RF
3000, Boston Scientific, Natick, MA, USA), a grounding
pad (conductive plates measuring 8.0 × 16.5 cm; GPS Srl,
Mozzo, Italy) and active electrodes. In the 2008 treatment
session, we performed the procedure using a flexible,
RFA, 2.8-mm, cooled-wet electrode. The active tip is
a stiff, straight, hollow 2.8-mm, stainless steel cannula
which contains a single monopolar electrode and a perfu-
sion system in a single device (Figure 1). In February 2013,
we used an expandable needle electrode (Miras TX model,
120 × 25 mm, 17-gauge), with stainless steel shafts (15 toFigure 1 Flexible radiofrequency ablation 2.8-mm cooled-wet
electrode used for radiofrequency ablation of the desmoid
tumours.25 cm long) insulated with a 0.1-mm-thick layer of plastic
and exposed tips (1.0 mm long). The shafts contain three
nickel titanium spiral extensions which can be fully or par-
tially deployed and retracted using a lever on the electrode
handle. The RFA technique that we performed was the
same as described elsewhere for the ablation of liver
tumours [12]. The procedure was performed with the
patient under general anaesthesia, induced following
best clinical practice norms. When using the flexible
RFA cooled-wet electrode, the tip was inserted under
ultrasonographic guidance into the distal part of the
tumour along the lesion’s major axis and retracted
using a pull-back technique. The generator was then
activated to deliver 70 to 100 W for 3 to 6 minutes.
When the 17-gauge, triple-spiral electrode was used,
the tip was inserted perpendicular to the lesion, ad-
vanced until the tip was seen in the centre of the tumour,
and deployed. The radiofrequency generator was then
activated to deliver 20 to 50 W for 6 to 12 minutes. To
ensure ablation of the full circumference and to avoid
causing burns, we cooled the skin over the tumour with
ice throughout the procedure (Figure 2). When the hyper-
echoic zone around the electrode tip was as large as the
tumour, the procedure was terminated and the electrode
was withdrawn. The patient’s pain was self-limiting, and
the only complication was a small first-degree burn at the
point of insertion of the electrode needle. Since this
procedure, there has been no recurrence of DTs after
18 months of follow-up at our centre (Figure 3). The
patient is in good clinical condition and receiving
routine follow-up. For the imaging modality during
the follow-up, we used ultrasonography and contrast-
enhanced ultrasonography.
Conclusions
In patients with GS, the treatment of DTs is an unre-
solved problem. Even if DTs are histologically benign
in GS, they have real clinical malignancy. Many therapies
have been proposed—surgical resection, pharmacotherapyFigure 2 Intraoperative photography taken during the
radiofrequency ablation procedure performed with
ultrasonographic guidance.
Figure 3 Postoperative contrast-enhanced ultrasonographic image. Double image that shows the results after radiofrequency ablation of
the desmoid tumour under contrast-enhanced ultrasonographic guidance (SonoVue; Bracco Imaging, Milan, Italy). The absence of contrast
enhancement demonstrates the successful treatment.
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tory outcomes. The first-line therapy for patients with
locally circumscribed DTs remains surgical resection. The
standard surgical goal is complete resection with negative
microscopic margins, but wide resection can result in de-
bilitating loss of function. The boundaries of the tumours
are difficult to distinguish intraoperatively from scars and
connective tissue, so R0 resection is not always possible,
and, consequently, adjuvant radiotherapy is often applied
[14]. In particular, surgery has been related to an increased
incidence of recurrence, and some authors have demon-
strated the role of surgical trauma in DT formation in GS
[15,16]. To avoid mutilating surgical interventions and the
potential negative effects of surgical trauma, various phar-
macotherapeutic approaches have been proposed—hor-
monal therapy, nonsteroidal anti-inflammatory drugs (for
example, celecoxib and sulindac), cytotoxic chemotherapy
and tyrosine kinase inhibitors, such as imatinib and soraf-
enib—but none have produced successful results [17,18].
In all therapies, the primary aim is to preserve the patient’s
quality of life. To date, treatment of DTs remains con-
troversial, and an optimal therapeutic protocol for this dis-
ease has not been established. Because of the rarity DTs
and the practical limitations in conducting research on
them, they often evade accurate characterization. On the
basis of the previous considerations, we attempted two
minimally invasive treatments for our patient—percutan-
eous cryoablation and RFA. Percutaneous cryoablation
has been shown to be an effective alternative treatment
for the local control of small and moderately sized extra-
abdominal DTs, although it is contraindicated in patients
with large tumours involving vital structures [19]. The
ablation treatment of a series of patients with paraspinal
and limb DTs has recently been reported. RFA wasreported to have produced effective local control with no
recurrence and only one complication of superficial skin
necrosis in 30 months of follow-up [15,16,20-23]. In
another recent study, the authors reported the use of this
technique to debulk and palliate an abdominal wall DT in
a patient with FAP [24]. Compared with surgery, RFA is
less invasive and less expensive, requires a shorter anaes-
thesia time and does not require use of an operating room.
We decided to introduce RFA as a treatment option to
destroy tissue without stimulating neuromuscular reac-
tion. On the basis of our experience and the recent litera-
ture, we propose that RF thermoablation stands as a
possible therapeutic option in the highly challenging treat-
ment of DTs in patients with GS. We need to perform
more of these procedures to define clearly the role of this
approach in the treatment of patients with DTs.
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